Trial · NCT02424253

A Study to Determine the Efficacy of ZPL-3893787 in Subjects With Atopic Dermatitis

NCT02424253, Phase 2, Completed, Ziarco Pharma Ltd; results first posted 2021-05-13

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. A Study to Determine the Efficacy of ZPL-3893787 in Subjects With Atopic Dermatitis. Trials, record NCT02424253. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02424253

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: A Study to Determine the Efficacy of ZPL-3893787 in Subjects With Atopic Dermatitis
NCT number: NCT02424253
Status: Completed
Phases: Phase 2
Enrollment: 98 participants, actual
Lead sponsor: Ziarco Pharma Ltd
Conditions: Atopic Dermatitis
Interventions: ZPL-3893787, Placebo
First posted: 2015-04-23
Last updated: 2021-06-10
Results first posted: 2021-05-13

Source ClinicalTrials.gov

Registered outcomes2

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Change From Baseline in the Numerical Rating Score (NRS) for Pruritus (Worst Itch)	Baseline to Week 8	The participant used the Pruritus NRS to rate his or her worst itch in the previous 12 hours. This was assessed twice daily (in the morning soon after rising and the evening prior to retiring) and recorded in the eDiary. The scale ranges from 0 (no itching) to 10 (itching as bad as can be imagined). If only 1 measurement was collected on a particular day, that score was counted as the worst measurement.
Secondary	Change From Baseline in Eczema Area and Severity Index (EASI) Score	Baseline to Week 8	The EASI is a validated tool used to measure the severity and extent of atopic eczema over 4 body regions (head and neck, upper limbs, trunk, and lower limbs). The intensity of a representative area of eczema and the approximate percentage affected by eczema are calculated for each region. A representative area of eczema is selected for each body region. The intensity of redness (erythema), thickness (induration, papulation, and edema), scratching (excoriation), and lichenification (lined skin) of eczema is assessed as: 0 - None 1. \- Mild 2. \- Moderate 3. \- Severe The total score incorporates the extent of body regions affected. Scores range from 0 to 72 with higher scores indicating more severe eczema. Total score is calculated by summing the EASI scores of 6 symptoms across 4 body regions

Source ClinicalTrials.gov

Outcomes2

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Change From Baseline in the Numerical Rating Score (NRS) for Pruritus (Worst Itch)	Baseline to Week 8	Full Analysis Set (FAS): Included all randomized subjects who received at least 1 dose of study drug.	score on a scale	MEAN
SECONDARY	Change From Baseline in Eczema Area and Severity Index (EASI) Score	Baseline to Week 8	FAS: All randomized subjects who received at least one dose of study treatment.	score on a scale	MEAN

Source ClinicalTrials.gov

Results by group12

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Change From Baseline in the Numerical Rating Score (NRS) for Pruritus (Worst Itch)	ZPL-3893787	Baseline summary	7.3	Standard Deviation 1.139	score on a scale
Change From Baseline in the Numerical Rating Score (NRS) for Pruritus (Worst Itch)	Placebo	Baseline summary	7.26	Standard Deviation 1.054	score on a scale
Change From Baseline in the Numerical Rating Score (NRS) for Pruritus (Worst Itch)	ZPL-3893787	Week 8 summary	4.27	Standard Deviation 2.253	score on a scale
Change From Baseline in the Numerical Rating Score (NRS) for Pruritus (Worst Itch)	Placebo	Week 8 summary	4.6	Standard Deviation 1.95	score on a scale
Change From Baseline in the Numerical Rating Score (NRS) for Pruritus (Worst Itch)	ZPL-3893787	Change from Baseline	-3.03	Standard Deviation 2.186	score on a scale
Change From Baseline in the Numerical Rating Score (NRS) for Pruritus (Worst Itch)	Placebo	Change from Baseline	-2.66	Standard Deviation 2.057	score on a scale
Change From Baseline in Eczema Area and Severity Index (EASI) Score	ZPL-3893787	Baseline	21.39	Standard Deviation 7.889	score on a scale
Change From Baseline in Eczema Area and Severity Index (EASI) Score	Placebo	Baseline	20.44	Standard Deviation 6.868	score on a scale
Change From Baseline in Eczema Area and Severity Index (EASI) Score	ZPL-3893787	Week 8 summary	10.67	Standard Deviation 9.541	score on a scale
Change From Baseline in Eczema Area and Severity Index (EASI) Score	Placebo	Week 8 summary	15.06	Standard Deviation 11.159	score on a scale

1 to 10 of 12Source ClinicalTrials.gov

See all 12 results by group

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	ZPL-3893787	65
Overall Study	STARTED	Placebo	33
Overall Study	COMPLETED	ZPL-3893787	54
Overall Study	COMPLETED	Placebo	24
Overall Study	NOT COMPLETED	ZPL-3893787	11
Overall Study	NOT COMPLETED	Placebo	9

Source ClinicalTrials.gov

Adverse events50

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Bradycardia	Cardiac disorders	ZPL-3893787	1	65
other	Bradycardia	Cardiac disorders	Placebo	0	33
other	Sinus arrhythmia	Cardiac disorders	ZPL-3893787	1	65
other	Sinus arrhythmia	Cardiac disorders	Placebo	0	33
other	Sinus bradycardia	Cardiac disorders	ZPL-3893787	1	65
other	Sinus bradycardia	Cardiac disorders	Placebo	0	33
other	Headache	Nervous system disorders	ZPL-3893787	6	65
other	Headache	Nervous system disorders	Placebo	4	33
other	Somnolence	Nervous system disorders	ZPL-3893787	2	65
other	Somnolence	Nervous system disorders	Placebo	1	33

1 to 10 of 50Source ClinicalTrials.gov

See all 50 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	ZPL-3893787	0	65
Total, all-cause mortality	Placebo	0	33
Total, other adverse events	ZPL-3893787	15	65
Total, other adverse events	Placebo	10	33
Total, serious adverse events	ZPL-3893787	0	65
Total, serious adverse events	Placebo	1	33

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons2

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
ZPL-3893787 vs Placebo: deaths from any cause	Trial comparisons
ZPL-3893787 vs Placebo: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT02424253

GET https://conductscience.org/api/trials/v1/NCT02424253/events?page=2

API reference For AI assistants